All In Biotech

Drug Trial Radar · NCT04798989

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology

Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

12

Actual

Start

Nov 2, 2021

Primary completion

Nov 28, 2022

Study completion Nov 28, 2022

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.

Conditions

  • Alzheimer's Disease With Vascular Pathology

Interventions

  • CY6463Drug

    CY6463 Oral Tablet

  • PlaceboDrug

    Placebo Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-upTime frame: From first dose of study treatment through ~14 (±4) days after the final dose

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Endpoints

    Scottsdale, Arizona

  • Optimus U Corp

    Miami, Florida

  • Hawaii Pacific Neurosciences, LLC

    Honolulu, Hawaii

  • University of Kentucky

    Lexington, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.